Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by Analysts at started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVFree Report) in a report issued on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

NASDAQ:NBRV opened at $1.42 on Friday. The company has a fifty day simple moving average of $0.14 and a two-hundred day simple moving average of $0.61. The company has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45.

Hedge Funds Weigh In On Nabriva Therapeutics

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its position in shares of Nabriva Therapeutics plc (NASDAQ:NBRVFree Report) by 102.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 795,938 shares of the biotechnology company’s stock after purchasing an additional 402,144 shares during the period. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.27% of the stock is currently owned by institutional investors.

Nabriva Therapeutics Company Profile

(Get Free Report)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.

Featured Articles

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.